FIELD: biotechnology.
SUBSTANCE: present invention relates to production of peptides capable of activating glucagon-like receptor-1 (GLP-1) receptor and glucagon receptor, and can be used in medicine for preventing or treating obesity.
EFFECT: invention provides producing a peptide having higher activity on GLP-1 and glucagon receptors as compared to native oxyntomodulin with reduced side effects.
8 cl, 1 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATE CONTAINING OXINTOMODULIN AND IMMUNOGLOBULIN FRAGMENT, AND ITS APPLICATION | 2012 |
|
RU2733544C2 |
| COMPOSITION FOR TREATING HYPERLIPIDEMIA CONTAINING AN OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2768853C1 |
| PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
| LONG-ACTING DOUBLE AGONIST OF GLUCAGON-LIKE PEPTIDE-1 AND GLUCAGON RECEPTORS | 2021 |
|
RU2799327C1 |
| MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF | 2020 |
|
RU2816492C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| PHARMACEUTICAL COMPOSITION INCLUDING A POLYPEPTIDE | 2019 |
|
RU2777095C1 |
| LONG-ACTING CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS | 2018 |
|
RU2779314C2 |
| PROTEINS WITH A DOUBLE FUNCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2016 |
|
RU2741345C2 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
